Efficacy, Tolerance and Satisfaction With CLOBEX® Spray When Used as Monotherapy or Add-on Therapy in Plaque Psoriasis

Inclusion Criteria: * Moderate to severe plaque psoriasis between 3% and 20% of Body Surface Area (BSA) with a target plaque severity (TPS) of moderate to severe * At least 1 target site (not on the palms or soles of the feet) with a TPS rating of moderate to severe and with 1 or more elevated, easily palpable, plaques having well-circumscribed margins, and at least 1 cm in diameter * History of stable plaque psoriasis of greater than or equal to 3 months Exclusion Criteria: * Diagnosis of guttate, generalized pustular, erythrodermic, psoriatic arthritis, or nail psoriasis as the sole or predominant form of psoriasis * Psoriatic arthritis that was not stable or might have required a change in medication during the 4-week study period * Plaque psoriasis requiring treatment on the face, scalp, neck, groin, and armpits